The research team performed a literature search on MEDLINE and EMBASE, from their inception through May 2017. They included studies that reported odds ratios or relative risks comparing the risk of developing CDI and/or the clinical outcomes of CDI in patients who received statins treatment versus those who did not receive statins.
They examined 10 observational studies that included 37,109 patients.
Researchers found statins reduced the risk of CDI development compared to no treatment. However, among patients who developed CDI, the use of statins did not significantly reduce risk of recurrent CDI. The research also did not show a link between statins use and reduced CDI severity, when compared to no use of statins.
More articles on healthcare quality:
CDC: Influenza activity low at start of flu season
Gov. Jerry Brown declares state of emergency over California’s hep A outbreak
Top 10 infection control stories, Oct. 9-13
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
